StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/309% above fair value
$78.68−1.60 (-1.99%)

Close on Nov 16, 2026Market cap $3.45BP/E –Yield 0.00%

Tarsus Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Tarsus Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -7.7%. For fiscal 2025 it was -14.7%, against -63.2% the year before. The highest annual figure on record is -14.7% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-14.7%+48.4
FY2024Dec 31, 2024-63.2%+715.7
FY2023Dec 31, 2023-778.9%−538.4
FY2022Dec 31, 2022-240.5%−216.3
FY2021Dec 31, 2021-24.2%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-10.7%+9.1
Q1 FY2026Mar 31, 2026-4.3%+27.8
Q4 FY2025Dec 31, 2025-5.5%+29.3
Q3 FY2025Sep 30, 2025-10.6%+38.1
Q2 FY2025Jun 30, 2025-19.8%+61.8
Q1 FY2025Mar 31, 2025-32.1%+97.3
Q4 FY2024Dec 31, 2024-34.8%+285.6
Q3 FY2024Sep 30, 2024-48.7%+2043.7
Q2 FY2024Jun 30, 2024-81.6%+855.2
Q1 FY2024Mar 31, 2024-129.4%+6.6
Q4 FY2023Dec 31, 2023-320.4%−282.9
Q3 FY2023Sep 30, 2023-2092.4%+1662.4
Q1 FY2023Mar 31, 2023-936.8%+3457.0
Q4 FY2022Dec 31, 2022-136.0%+1129.9
Q2 FY2022Jun 30, 2022-37.6%−66.4
Q1 FY2022Mar 31, 2022-3754.7%−3785.8
Q4 FY2021Dec 31, 2021-4393.8%–
Q3 FY2021Sep 30, 2021-1265.9%–
Q2 FY2021Jun 30, 202128.8%–
Q1 FY2021Mar 31, 202131.0%–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?